News

SHP654 is an investigational factor VIII (FVIII) gene therapy, which will protect hemophilia A patients against bleeds through delivering long-term and constant level of factor expression. Shire had

Tonix recently launched the Phase 3 HONOR study of Tonmya in military-related PTSD, from which topline results are expected to be reported in the second half of 2018.

This is the company's fourth product candidate to receive orphan drug designation from the FDA. Rett syndrome is a rare and severe genetic neurodevelopmental disorder affecting females almost

PRX002/RG7935 is an anti-alpha-synuclein antibody under investigation as a disease-modifying treatment for Parkinson's disease and is the focus of a worldwide collaboration between Prothena and Roche. The start

Top-line results from the HEALOS trial are expected in the fall of 2017. "We are very pleased that our first Phase 3 clinical trial of AM-111 is now

The deal will pertain to treating patients with BGB-A317 in the US, Europe, Japan and rest of world outside Asia. In this regard, BeiGene will receive a total

The clinical hold has been placed on Keynote-183, Keynote-185 and Keynote-023 combination studies of the anti-PD-1 therapy, Keytruda, to treat blood cancer multiple myeloma. FDA has decided to

The funding agreement was announced today in a positive final evaluation determination (FED) issued by the NICE Highly Specialised Technologies (HST) Evaluation Committee to recommend Strensiq according to

Dasiglucagon is a potential first-in-class glucagon analog invented and developed by Zealand. It has a unique stability profile in liquid formulation and is suitable for a ready-to-use rescue